Prior GLP‐1 agonist use is not associated with adverse inpatient critical care outcomes: A propensity‐matched analysis
Journal of Hospital Medicine · 2025
DOI: 10.1002/jhm.70228 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Hospital Medicine, 2025. Verfasst von Albert K Park und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Stanford University Medical Center, Stanford, California, USA. Hauptthemen laut MEDLINE: Glucagon-Like Peptide 1, Critical Care Outcomes, Critical Care. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: None.
Abstract (Originalsprache)
Background
Glucagon‐like peptide‐1 (GLP‐1) agonists are increasingly prescribed for obesity and type 2 diabetes. GLP‐1 agonists influence body composition through effects on both fat mass and fat‐free mass. Given that critically ill patients experience severe protein catabolism and commonly develop intensive care unit (ICU)‐acquired weakness, questions arise about outcomes when metabolic demands are high during critical illness.
Objective
The objective of this study is to examine the relationship between prior GLP‐1 agonist use and critical care outcomes.
Methods
We conducted a retrospective cohort study using Stanford Health Care data from January 2015 to July 2024. Adults aged 18–89 years admitted to intensive care with body mass index (BMI) 20–60 kg/m 2 were included. Of 15,191 eligible ICU patients, 468 (3.1%) received GLP‐1 agonist prescriptions within 12 months before hospitalization. Using high‐dimensional propensity score matching with lasso regression, we created 452 matched pairs and compared in‐hospital mortality, hospital length of stay, and ICU length of stay between groups.
Results
Baseline characteristics were well‐balanced. The matched GLP‐1 agonist and comparison groups showed similar in‐hospital mortality (5.1% vs. 4.9%, odds ratio [OR]: 1.05, 95% confidence interval [CI]: 0.58 to 1.91, p = .88), mean hospital length of stay (13.7 ± 21.3 vs. 13.4 ± 18.1 days, mean difference [MD]: 0.38, 95% CI: −2.21 to 3.05, p = .77), and ICU length of stay (5.9 ± 9.0 vs. 5.4 ± 6.6 days, MD: 0.51, 95% CI: –0.52 to 1.50, p = .33).
Conclusions
In this first study examining the relationship between prior GLP‐1 agonist use and critical care outcomes, we found no significant associations with in‐hospital mortality, hospital length of stay, or ICU length of stay.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Stanford University Medical Center, Stanford, California, USA.
- Department of Anesthesiology, Perioperative and Pain Medicine, Division of Anesthesia Critical Care, Stanford University Medical Center, Stanford, California, USA.
- Atropos Health, Palo Alto, California, USA.
- Eucalyptus, Sydney, Australia.
ORCID-Profile: Albert K Park
Förderung
- None
Zitieren
APA
Park, A. K., Hom, J., Lorenzo, J., Rao, V., Hui, G., Vickers, M., & Ahuja, N. (2025). Prior GLP‐1 agonist use is not associated with adverse inpatient critical care outcomes: A propensity‐matched analysis. Journal of Hospital Medicine. https://doi.org/10.1002/jhm.70228
Vancouver
Park AK, Hom J, Lorenzo J, Rao V, Hui G, Vickers M, et al. Prior GLP‐1 agonist use is not associated with adverse inpatient critical care outcomes: A propensity‐matched analysis. Journal of Hospital Medicine. 2025. doi:10.1002/jhm.70228
BibTeX
@article{Park2025,
author = {Park, Albert K and Hom, Jason and Lorenzo, Javier and Rao, Vidya and Hui, Gavin and Vickers, Matthew and Ahuja, Neera},
title = {Prior GLP‐1 agonist use is not associated with adverse inpatient critical care outcomes: A propensity‐matched analysis},
journal = {Journal of Hospital Medicine},
year = {2025},
doi = {10.1002/jhm.70228}
}
EUVIMED